Skip to main content
. 2016 Dec 9;6:38694. doi: 10.1038/srep38694

Figure 3. Comparison of the activities of BA transporters between hiHeps and human hepatocytes.

Figure 3

(A) The efflux transporter activities of BSEP and MRP2 were determined by calculating the BEI values of d8-TCA (the substrate of BSEP) and methotrexate (the substrate of MRP2) for hiHeps (white columns) and SCHHs (black columns). The data are expressed as the mean ± SD (n = 3). (B) The polarized locations of efflux transporters in the bile canaliculi of both hiHeps and SCHHs, as determined by fluorescence microscopy. In the absence or presence of MK571 (20 μmol/L), an MRP2 inhibitor, bile canaliculi were labelled with an MRP2 fluorescent substrate, CDF, which was formed from non-fluorescent CDFDA via intracellular esterases. (C) The influx transporter activity of NTCP was determined by accumulation assay of an NTCP substrate, d8-TCA. Troglitazone (10 μmol/L) was used as a positive control. The data are expressed as the mean ± SD (n = 3). *p < 0.05 vs control in hiHeps, #p < 0.05 vs control in PHHs.